Irreversible EGFR Inhibitors in the Treatment of Advanced NSCLC

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|24|3894-3900

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.24, 2014-05, pp. : 3894-3900

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cell cycle inhibitors for the treatment of NSCLC

By Shcherba Marina   Liang Yuanxin   Fernandes David   Perez-Soler Roman   Cheng Haiying  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 7, 2014-05 ,pp. : 991-1004

Informa Healthcare

Access to resources Recommend Favorite

The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation

By  

Current Medicinal Chemistry, Vol. 19, Iss. 20, 2012-07 ,pp. : 3337-3352

Bentham Science Publishers

Access to resources Recommend Favorite

The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial

By Gridelli Cesare   Di Maio Massimo  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 321-324

Informa Healthcare

Access to resources Recommend Favorite

Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment

By  

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 19, 2016-08 ,pp. : 2179-2188

Bentham Science Publishers

Access to resources Recommend Favorite

Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better…

By  

Current Pharmaceutical Design, Vol. 20, Iss. 24, 2014-05 ,pp. : 3901-3913

Bentham Science Publishers

Access to resources Recommend Favorite